SubsidieMeestersRevolutionary therapeutic treatment for stopping progression of Parkinson's disease
Herantis is developing HER-096, a novel pharmaceutical aimed at modifying Parkinson's disease pathology to alleviate symptoms and reduce the societal burden of the condition.
Projectdetails
Introduction
Parkinson's disease (PD) is a common neurodegenerative disorder, affecting over 10 million people worldwide, including 1.2 million in the EU. This chronic disabling disease affects the central nervous system, causing severe motor and non-motor symptoms.
Economic Impact
The high disease burden for patients and their families also comes with a significant price tag for society, which is expected to increase dramatically with an ageing population. In the EU, the annual cost is currently 14 billion euros.
Pathophysiology
The causes of PD are unknown, and there is a broad spectrum of pathologies that ultimately lead to the loss of dopamine-producing neurons in the brain.
Current Treatments
The current dopamine substitution treatments alleviate some of the symptoms; however, there is no cure for PD nor any disease-modifying therapies.
Innovative Solution
Herantis has developed a new pharmaceutical, HER-096, with the ability to affect PD pathology and the potential to revolutionize the treatment of PD, thus alleviating the huge burden it currently imposes on patients and healthcare systems.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.500.000 |
| Totale projectbegroting | € 4.083.500 |
Tijdlijn
| Startdatum | 1-5-2023 |
| Einddatum | 30-4-2025 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- HERANTIS PHARMA OYJpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative DiseaseThe project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens. | EIC Pathfinder | € 2.992.203 | 2022 | Details |
Interrogating basal ganglia reinforcement with deep brain stimulation in Parkinson’s disease.ReinforceBG aims to explore dopamine's role in Parkinson's disease through advanced neuromodulation techniques to enhance understanding and develop innovative treatments for motor and cognitive symptoms. | ERC STG | € 1.499.580 | 2023 | Details |
Unraveling Parkinson´s disease diagnosticUNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden. | ERC POC | € 150.000 | 2024 | Details |
Novel small molecule attenuator of neuroinflammation in Parkinson’s DiseaseNEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap. | ERC POC | € 150.000 | 2025 | Details |
Opto-Electronic Neural Connectoid Model Implemented for Neurodegenerative Disease
The project aims to develop a novel human brain-organoid model, called connectoids, to replace animal testing for Parkinson's disease, enhancing therapy monitoring and reducing societal burdens.
Interrogating basal ganglia reinforcement with deep brain stimulation in Parkinson’s disease.
ReinforceBG aims to explore dopamine's role in Parkinson's disease through advanced neuromodulation techniques to enhance understanding and develop innovative treatments for motor and cognitive symptoms.
Unraveling Parkinson´s disease diagnostic
UNMASK aims to validate a non-invasive, olfaction-inspired technology for fast Parkinson's disease diagnostics, addressing the need for timely detection and reducing its social and economic burden.
Novel small molecule attenuator of neuroinflammation in Parkinson’s Disease
NEUROSHIELD aims to develop a novel small molecule targeting neuroinflammation in Parkinson's disease to improve patient quality of life and address a significant treatment gap.